Skip to main content
VOR logo

VOR · Vor Biopharma Inc. · Holdings

Track VOR — free
$18.52 +0.69 (+3.87%)
Market Cap
$1.14B
Shares
61.43M
Volume · Nov 19 825.77K Avg daily vol (3M) 926.93K

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Holders: 158
Total Value: $1,055,195,004
Total Shares: 55,303,727
Showing 1–100 of 162 holdings by value · page 1 of 2

Institutional Ownership Trend

23 quarters

Holder Concentration

Share of 13F common-share value, across 158 filers with any position, options included · Δ vs Jun 30, 2026
Top Holder
12.2%
Dec 2023 → Sep 2026 · range 11.7% – 69.5%
+0.5 pts
Top 5
42.8%
Dec 2023 → Sep 2026 · range 42.8% – 92.2%
−1.0 pts
Top 10
63.9%
Dec 2023 → Sep 2026 · range 63.9% – 96.4%
−3.7 pts
HHI
525
Dec 2023 → Sep 2026 · range 525 – 4,989
Broadly held−46

Who Holds VOR

Last 8 quarters through Sep 30, 2026

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Sep 30, 2026: 156 filers, like-for-like change +14.0%; actively managed books +19.0%; index-like books -3.9%.

Holder type Share Filers Change
Registered adviser 46.5% 78 +16.8%
Exempt adviser 1.8% 4 +84.0%
Adviser 3.3% 6 +1844.3%
Bank 5.7% 14 -17.7%
Broker-dealer 0.0% 1 -4.4%
Benefit plan 0.1% 2 +12874.9%
Non-US 0.2% 5 +55.8%
Holding company 20.0% 7 +25.3%
Unknown 22.4% 39 -5.7%
How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Excluded 2 holders with no observed 2026-06-30 13F and 1 holder with no observed 2026-09-30 13F.

Conviction and Crowding

156 13F filers, quarter ended Sep 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
6
3.85% of filers hold it in their top 10
Jun 30, 2026: 5
Holders above 5%
3
median weight 0.001%
Jun 30, 2026: 3
Crowding
39.2%
of shares outstanding, 90th percentile
Jun 30, 2026: 35.8%
Private-fund advisers
38.5%
of shares outstanding
Institutional ownership
93.5%
106.0% of the estimated free float above 100%: filers can report lent or client shares more than once
Top 10 holders
63.9%
of 13F shares, Herfindahl 0.052
Active holders
+19.0%
like-for-like share change of active filers
5% stakes on record
8
3 13D, 5 13G (2 institutional, 3 passive, 0 exempt)
How long holders have held it value-weighted 9.0 quarters
Under 1 year 35.6% 1 to 3 years 36.7% 3 years or more 27.7% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net buyers of $26,121,708 (13 buying, 8 selling).

Estimated Holder Cost Basis

Quarter ended Sep 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$27.17
estimated per share
Jun 30, 2026: $27.78
Quarter-end price
$19.08
implied by 13F values
Estimated gain or loss
-29.8%
price against the estimated cost
Estimated at a loss
35.5%
of costed 13F value

Estimated cost covers 54.9% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies VOR's active holders also own, quarter ended Sep 30, 2026
# Company Shared holders
1 LBRX Lb Pharmaceuticals Inc 10
2 AMAN Amanat Acquisition Corp. 6
3 OVID Ovid Therapeutics Inc. 8
4 TCGX TCGX Acquisition Corp. 9
5 AURA Aura Biosciences, Inc. 9
6 MNPR Monopar Therapeutics 6
7 SVRA Savara Inc 10
8 KRSA Korsana Biosciences, Inc. 8
9 JATT JATT II Acquisition Corp. 6
10 CLYM Climb Bio, Inc. 7

Shareholder Targets

13F filers that own its peers but not VOR, quarter ended Sep 30, 2026

Found through its holder-overlap peers: LBRX, AMAN, OVID, TCGX, AURA, MNPR, SVRA, KRSA, JATT, CLYM, IFRX, JTTT, ABVX, PCVX, DMRA, ORIC, AVTX, CUE, EDIT, ENTX. 609 filers in all.

# Filer In peers
1 T. Rowe Price Investment Management, Inc. Adviser, Diversified active $813,670,227 1 held
2 Fairmount Funds Management LLC Registered adviser, Concentrated $476,731,968 2 held
3 Vestal Point Capital, LP Registered adviser, Concentrated $438,236,160 5 held
4 Helikon Investments Ltd Unknown, Concentrated $418,151,161 1 held
5 Deep Track Capital, LP Adviser, Diversified active $399,759,894 6 held
6 Darwin Global Management, Ltd. Exempt adviser, Concentrated $398,217,148 1 held
7 WESTFIELD CAPITAL MANAGEMENT CO LP Registered adviser, Diversified active $350,159,042 2 held
8 Bellevue Group AG Non-US, Diversified active $209,706,902 6 held
9 Commodore Capital LP Registered adviser, Concentrated $203,236,675 9 held
10 Balyasny Asset Management L.P. Registered adviser, Systematic-like $192,863,761 11 held

Fund Ownership of VOR by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 9.83% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 1.07% 659,839
Index ETFs 8.76% 5,379,416
Active ETFs 0.00% 339
Active funds 2.54% 1,562,632
Unclassified 0.00% 0
All registered funds 12.37% 7,602,226
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Quarterly Activity

vs Jun 30, 2026
New
67
Increased
42
Decreased
37
Sold Out
12
Unchanged
10

New and Sold Out count only filers that reported a 13F for both quarters: a first-time filer's book is not a buy, and a fund that has not filed, or withheld its positions under confidential treatment, has not sold.

Holder count: +56
Institutional value: +18.2%
Shares held: +14.0%

Top Buyers

vs Jun 30, 2026
Institution Added Now Holds Open

Top Sellers

vs Jun 30, 2026
Institution Sold Now Holds Open

Top New Positions

vs Jun 30, 2026
Institution Acquired Value (USD) Open

Top Sold-Out Positions

vs Jun 30, 2026
Institution Previously Held Last Value (USD) Open
Showing 100 of 162
Export CSV
Holder Value (USD) % of 13F Shares Own % Change Type Filed Open

Showing the top 100 of 162 holders. Create a free account to see every holder, past quarters, search, filters and CSV export.

Key facts CIK 1817229 CUSIP 929033207 13F (30d) 166 filings 151 filers Visit website Investor relations